IL93840A - Monoclonal antibodies from the GGI1 subgroup that accompany cells that are carcinogenic to the lungs or colon of humans, their production, and preparations, pharmaceutics and vaccines that contain them - Google Patents

Monoclonal antibodies from the GGI1 subgroup that accompany cells that are carcinogenic to the lungs or colon of humans, their production, and preparations, pharmaceutics and vaccines that contain them

Info

Publication number: IL93840A
Authority: IL; Israel
Prior art keywords: antibody; monoclonal antibody; antigen; cells; human
Prior art date: 1989-04-17

Application number

IL9384090A

Other languages

English (en)

Hebrew (he)

Other versions

IL93840A0 (en

Original Assignee

Oncogen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-04-17

Filing date

1990-03-22

Publication date

1995-07-31

1990-03-22 Application filed by Oncogen filed Critical Oncogen

1990-12-23 Publication of IL93840A0 publication Critical patent/IL93840A0/xx

1995-07-31 Publication of IL93840A publication Critical patent/IL93840A/en

Links

206010009944 Colon cancer Diseases 0.000 title claims description 27
210000004072 lung Anatomy 0.000 title claims description 26
206010058467 Lung neoplasm malignant Diseases 0.000 title claims description 15
201000005296 lung carcinoma Diseases 0.000 title claims description 15
229960005486 vaccine Drugs 0.000 title claims description 11
238000004519 manufacturing process Methods 0.000 title description 6
239000008194 pharmaceutical composition Substances 0.000 title description 4
239000000427 antigen Substances 0.000 claims description 124
108091007433 antigens Proteins 0.000 claims description 124
102000036639 antigens Human genes 0.000 claims description 124
210000004027 cell Anatomy 0.000 claims description 111
206010028980 Neoplasm Diseases 0.000 claims description 74
238000000034 method Methods 0.000 claims description 52
210000004881 tumor cell Anatomy 0.000 claims description 40
230000027455 binding Effects 0.000 claims description 39
210000004408 hybridoma Anatomy 0.000 claims description 32
201000009030 Carcinoma Diseases 0.000 claims description 25
210000001072 colon Anatomy 0.000 claims description 16
150000001413 amino acids Chemical class 0.000 claims description 15
230000000890 antigenic effect Effects 0.000 claims description 15
238000001514 detection method Methods 0.000 claims description 15
238000010186 staining Methods 0.000 claims description 12
206010035226 Plasma cell myeloma Diseases 0.000 claims description 11
201000000050 myeloid neoplasm Diseases 0.000 claims description 11
102000003886 Glycoproteins Human genes 0.000 claims description 10
108090000288 Glycoproteins Proteins 0.000 claims description 10
102000012750 Membrane Glycoproteins Human genes 0.000 claims description 9
108010090054 Membrane Glycoproteins Proteins 0.000 claims description 9
241000700605 Viruses Species 0.000 claims description 9
238000002264 polyacrylamide gel electrophoresis Methods 0.000 claims description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
208000029742 colonic neoplasm Diseases 0.000 claims description 8
210000004698 lymphocyte Anatomy 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 7
239000012634 fragment Substances 0.000 claims description 7
230000003993 interaction Effects 0.000 claims description 7
108090000790 Enzymes Proteins 0.000 claims description 6
102000004190 Enzymes Human genes 0.000 claims description 6
230000003053 immunization Effects 0.000 claims description 5
238000002649 immunization Methods 0.000 claims description 5
238000003018 immunoassay Methods 0.000 claims description 5
238000011725 BALB/c mouse Methods 0.000 claims description 4
241001529936 Murinae Species 0.000 claims description 4
241000700618 Vaccinia virus Species 0.000 claims description 4
201000010897 colon adenocarcinoma Diseases 0.000 claims description 4
239000012530 fluid Substances 0.000 claims description 4
210000004988 splenocyte Anatomy 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 4
210000001519 tissue Anatomy 0.000 description 24
201000011510 cancer Diseases 0.000 description 17
239000012528 membrane Substances 0.000 description 14
239000006228 supernatant Substances 0.000 description 13
241000699666 Mus <mouse, genus> Species 0.000 description 12
239000000203 mixture Substances 0.000 description 12
238000002560 therapeutic procedure Methods 0.000 description 12
230000009257 reactivity Effects 0.000 description 11
201000001441 melanoma Diseases 0.000 description 10
238000000338 in vitro Methods 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
239000000523 sample Substances 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
108091003079 Bovine Serum Albumin Proteins 0.000 description 8
238000003745 diagnosis Methods 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
241000283973 Oryctolagus cuniculus Species 0.000 description 7
238000003556 assay Methods 0.000 description 7
230000004927 fusion Effects 0.000 description 7
230000002163 immunogen Effects 0.000 description 7
208000026310 Breast neoplasm Diseases 0.000 description 6
241000283707 Capra Species 0.000 description 6
210000000481 breast Anatomy 0.000 description 6
238000010790 dilution Methods 0.000 description 6
239000012895 dilution Substances 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
238000007912 intraperitoneal administration Methods 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
238000007920 subcutaneous administration Methods 0.000 description 6
238000011282 treatment Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
206010003445 Ascites Diseases 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
239000003814 drug Substances 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
239000008188 pellet Substances 0.000 description 5
238000011160 research Methods 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
210000000952 spleen Anatomy 0.000 description 5
210000004989 spleen cell Anatomy 0.000 description 5
238000005406 washing Methods 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
206010063045 Effusion Diseases 0.000 description 4
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
206010025323 Lymphomas Diseases 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
208000009956 adenocarcinoma Diseases 0.000 description 4
230000000259 anti-tumor effect Effects 0.000 description 4
239000002246 antineoplastic agent Substances 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000002405 diagnostic procedure Methods 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
239000000499 gel Substances 0.000 description 4
208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
210000001672 ovary Anatomy 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
239000003053 toxin Substances 0.000 description 4
231100000765 toxin Toxicity 0.000 description 4
108700012359 toxins Proteins 0.000 description 4
206010006187 Breast cancer Diseases 0.000 description 3
238000012286 ELISA Assay Methods 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
229930186217 Glycolipid Natural products 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000013060 biological fluid Substances 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
229940044683 chemotherapy drug Drugs 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
210000004748 cultured cell Anatomy 0.000 description 3
230000034994 death Effects 0.000 description 3
231100000517 death Toxicity 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
210000001165 lymph node Anatomy 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
238000011580 nude mouse model Methods 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
101001035658 Mus musculus 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 description 2
101000785917 Mus musculus Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 Proteins 0.000 description 2
101000735426 Mus musculus Poly(A) RNA polymerase, mitochondrial Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
108010004729 Phycoerythrin Proteins 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
239000012148 binding buffer Substances 0.000 description 2
230000008827 biological function Effects 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
201000008275 breast carcinoma Diseases 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
230000000984 immunochemical effect Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
239000012133 immunoprecipitate Substances 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000004807 localization Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000003607 modifier Substances 0.000 description 2
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
QEIFSLUFHRCVQL-UHFFFAOYSA-N (5-bromo-4-chloro-1h-indol-3-yl) hydrogen phosphate;(4-methylphenyl)azanium Chemical compound CC1=CC=C(N)C=C1.C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QEIFSLUFHRCVQL-UHFFFAOYSA-N 0.000 description 1
125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
KJDSORYAHBAGPP-UHFFFAOYSA-N 4-(3,4-diaminophenyl)benzene-1,2-diamine;hydron;tetrachloride Chemical compound Cl.Cl.Cl.Cl.C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 KJDSORYAHBAGPP-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
241000713863 Kirsten murine sarcoma virus Species 0.000 description 1
108010023244 Lactoperoxidase Proteins 0.000 description 1
102000045576 Lactoperoxidases Human genes 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
102000015728 Mucins Human genes 0.000 description 1
108010063954 Mucins Proteins 0.000 description 1
FOCMISOLVPZNSV-CANPYCKCSA-N N-[(E,2R,3S)-1-[5-[5-[3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoctadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(O)C3NC(C)=O)C(O)C2O)C(O)C1O)[C@@H](O)\C=C\CCCCCCCCCCCCC FOCMISOLVPZNSV-CANPYCKCSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003302 anti-idiotype Effects 0.000 description 1
230000006023 anti-tumor response Effects 0.000 description 1
229940125644 antibody drug Drugs 0.000 description 1
238000011091 antibody purification Methods 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229940022399 cancer vaccine Drugs 0.000 description 1
238000009566 cancer vaccine Methods 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000003271 compound fluorescence assay Methods 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000010908 decantation Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000018732 detection of tumor cell Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
238000012631 diagnostic technique Methods 0.000 description 1
AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
150000002339 glycosphingolipids Chemical class 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
230000000951 immunodiffusion Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
239000000568 immunological adjuvant Substances 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
230000035992 intercellular communication Effects 0.000 description 1
230000010262 intracellular communication Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229940057428 lactoperoxidase Drugs 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
201000010893 malignant breast melanoma Diseases 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229940051875 mucins Drugs 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
230000008823 permeabilization Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
210000002729 polyribosome Anatomy 0.000 description 1
235000010241 potassium sorbate Nutrition 0.000 description 1
239000004302 potassium sorbate Substances 0.000 description 1
229940069338 potassium sorbate Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
229950008679 protamine sulfate Drugs 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000003156 radioimmunoprecipitation Methods 0.000 description 1
238000011363 radioimmunotherapy Methods 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
238000012552 review Methods 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000006152 selective media Substances 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
229940083538 smallpox vaccine Drugs 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000002639 sodium chloride Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000004960 subcellular localization Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
238000003325 tomography Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000001262 western blot Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer

IL9384090A 1989-04-17 1990-03-22 Monoclonal antibodies from the GGI1 subgroup that accompany cells that are carcinogenic to the lungs or colon of humans, their production, and preparations, pharmaceutics and vaccines that contain them IL93840A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/339,142 US5171665A (en)	1989-04-17	1989-04-17	Monoclonal antibody to novel antigen associated with human tumors

Publications (2)

Publication Number	Publication Date
IL93840A0 IL93840A0 (en)	1990-12-23
IL93840A true IL93840A (en)	1995-07-31

Family

ID=23327694

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9384090A IL93840A (en)	1989-04-17	1990-03-22	Monoclonal antibodies from the GGI1 subgroup that accompany cells that are carcinogenic to the lungs or colon of humans, their production, and preparations, pharmaceutics and vaccines that contain them

Country Status (12)

Country	Link
US (1)	US5171665A (el)
EP (1)	EP0597829A1 (el)
JP (1)	JPH04505102A (el)
KR (1)	KR920700692A (el)
AU (1)	AU639458B2 (el)
CA (1)	CA2014304A1 (el)
FI (1)	FI914908A0 (el)
GR (1)	GR1000477B (el)
IL (1)	IL93840A (el)
NZ (1)	NZ233325A (el)
PT (1)	PT93776A (el)
WO (1)	WO1990012594A1 (el)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5705157A (en) *	1989-07-27	1998-01-06	The Trustees Of The University Of Pennsylvania	Methods of treating cancerous cells with anti-receptor antibodies
US5250297A (en) *	1989-10-20	1993-10-05	Hybritech Incorporated	Tumor-associated antigen, antibodies, compositions and uses therefor
US8211422B2 (en) *	1992-03-18	2012-07-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric receptor genes and cells transformed therewith
US8791237B2 (en)	1994-11-08	2014-07-29	The Trustees Of The University Of Pennsylvania	Compositions and methods for treatment of non-hodgkins lymphoma
US8956621B2 (en)	1994-11-08	2015-02-17	The Trustees Of The University Of Pennsylvania	Compositions and methods for treatment of cervical dysplasia
US8114414B2 (en)	1994-11-08	2012-02-14	The Trustees Of The University Of Pennsylvania	Compositions and methods for treatment of cervical cancer
US7820180B2 (en)	2004-09-24	2010-10-26	The Trustees Of The University Of Pennsylvania	Listeria-based and LLO-based vaccines
EP0961780B1 (en) *	1997-02-12	2007-04-11	Electrophoretics Limited	Protein markers for lung cancer and use thereof
US6962702B2 (en)	1998-06-22	2005-11-08	Immunomedics Inc.	Production and use of novel peptide-based agents for use with bi-specific antibodies
US8383081B2 (en)	1999-05-10	2013-02-26	Immunomedics, Inc.	Anti-CD74 immunoconjugates and methods of use
US8119101B2 (en)	1999-05-10	2012-02-21	The Ohio State University	Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en)	1999-05-10	2010-11-09	Immunomedics, Inc.	Anti-CD74 immunoconjugates and methods
US6657048B2 (en) *	1999-10-08	2003-12-02	Arius Research, Inc.	Individualized anti-cancer antibodies
US20050100542A1 (en) *	1999-10-08	2005-05-12	Young David S.	Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) *	1999-10-08	2011-05-24	Hoffmann-La Roche Inc.	Cytotoxicity mediation of cells evidencing surface expression of CD44
US6180357B1 (en) *	1999-10-08	2001-01-30	Arius Research, Inc.	Individualized patient-specific anti-cancer antibodies
US20080124327A1 (en) *	1999-10-08	2008-05-29	Arius Research, Inc.	Cytotoxicity mediation of cells evidencing surface expression of CD44
US7252821B2 (en)	1999-10-08	2007-08-07	Arius Research Inc.	Cancerous disease modifying antibodies
US7419792B2 (en) *	1999-10-08	2008-09-02	Arius Research Inc.	Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
US20090004103A1 (en) *	1999-10-08	2009-01-01	Young David S F	Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) *	1999-10-08	2007-03-13	Arius Research Inc.	Cytotoxicity mediation of cells evidencing surface expression of CD44
US7442776B2 (en) *	1999-10-08	2008-10-28	Young David S F	Cancerous disease modifying antibodies
US7256271B2 (en)	2003-01-21	2007-08-14	Arius Research Inc.	Cancerous disease modifying antibodies
US6794494B1 (en)	2003-04-14	2004-09-21	Arius Research, Inc.	Cancerous disease modifying antibodies
US8071072B2 (en) *	1999-10-08	2011-12-06	Hoffmann-La Roche Inc.	Cytotoxicity mediation of cells evidencing surface expression of CD44
US20040001789A1 (en) *	1999-10-08	2004-01-01	Young David S. F.	Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
US8048416B2 (en)	1999-10-08	2011-11-01	Hoffmann-La Roche Inc.	Cytotoxicity mediation of cells evidencing surface expression of CD44
US20040105816A1 (en) *	1999-10-08	2004-06-03	Young David S. F.	Cancerous disease modifying antibodies
US9012141B2 (en)	2000-03-27	2015-04-21	Advaxis, Inc.	Compositions and methods comprising KLK3 of FOLH1 antigen
AU2001255196A1 (en)	2000-03-29	2001-10-08	The Trustees Of The University Of Pennsylvania	Compositions and methods for enhancing immunogenicity of antigens
US20020098516A1 (en) *	2000-10-03	2002-07-25	Boystown National Research Hospital	Immunodiagnostic determination of usher syndrome type IIA
US7009040B2 (en) *	2003-01-21	2006-03-07	Arius Research, Inc.	Cancerous disease modifying antibodies
US20060210474A1 (en) *	2000-11-29	2006-09-21	Young David S	Cytotoxicity mediation of cells evidencing surface expression of CD63
US7431923B2 (en) *	2005-01-03	2008-10-07	Arius Research Inc.	Cytotoxicity mediation of cells evidencing surface expression of CD63
US7361343B2 (en) *	2003-01-21	2008-04-22	Arius Research Inc.	Cytotoxicity mediation of cells evidencing surface expression of CD63
US7442777B2 (en) *	2000-11-29	2008-10-28	Arius Research Inc.	Cytotoxicity mediation of cells evidencing surface expression of CD63
US7534429B2 (en) *	2000-11-29	2009-05-19	Hoffmann-La Roche Inc.	Cytotoxicity mediation of cells evidencing surface expression of CD63
AUPR395801A0 (en) *	2001-03-26	2001-04-26	Austin Research Institute, The	Antibodies against cancer
US20090123470A1 (en) *	2001-03-26	2009-05-14	The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd.	Antibodies Against Cancer
US8771702B2 (en)	2001-03-26	2014-07-08	The Trustees Of The University Of Pennsylvania	Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en)	2001-03-26	2010-04-20	The Trustees Of The University Of Pennsylvania	Compositions and methods for enhancing the immunogenicity of antigens
WO2003072068A2 (en) *	2002-02-27	2003-09-04	University Of South Carolina	Targeted immunotherapy of acute lymphoblastic leukemia (all)
CN1649902B (zh)	2002-03-01	2011-04-13	免疫医疗公司	内在化抗-cd74抗体和使用方法
US9770517B2 (en)	2002-03-01	2017-09-26	Immunomedics, Inc.	Anti-Trop-2 antibody-drug conjugates and uses thereof
US8420086B2 (en)	2002-12-13	2013-04-16	Immunomedics, Inc.	Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US7488475B2 (en)	2003-01-21	2009-02-10	Arius Research, Inc.	Antibody therapy of tumors
US7175846B2 (en) *	2003-01-21	2007-02-13	Arius Research Inc.	Cancerous disease modifying antibodies
US7361342B2 (en) *	2003-01-21	2008-04-22	Arius Research Inc.	Cancerous disease modifying antibodies
US7393531B2 (en) *	2003-01-21	2008-07-01	Arius Research Inc.	Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7468254B2 (en) *	2003-01-21	2008-12-23	Arius Research Inc.	Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7195764B2 (en)	2003-04-14	2007-03-27	Arius Research Inc.	Cancerous disease modifying antibodies
US7399835B2 (en) *	2004-02-26	2008-07-15	Arius Research Inc.	Cancerous disease modifying antibodies
US20080025977A1 (en) *	2003-04-14	2008-01-31	Arius Research, Inc.	Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060140963A1 (en) *	2003-04-14	2006-06-29	Arius Research, Inc.	Cytotoxicity mediation of cells evidencing surface expression of CD59
US20080213169A1 (en) *	2003-04-14	2008-09-04	Arius Research, Inc.	Cytotoxicity mediation of cells evidencing surface expression of CD59
US7825085B2 (en) *	2003-06-30	2010-11-02	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cells
US20050027106A1 (en) *	2003-07-28	2005-02-03	Young David S. F.	Cancerous disease modifying antibodies
US9550838B2 (en)	2004-02-13	2017-01-24	Ibc Pharmaceuticals, Inc.	Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) *	2004-02-13	2014-11-11	Ibc Pharmaceuticals, Inc.	Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US7348413B2 (en) *	2004-02-26	2008-03-25	Arius Research Inc.	Cancerous disease modifying antibodies
US20050255041A1 (en) *	2004-05-13	2005-11-17	Arius Research, Inc.	Cancerous disease modifying antibodies
US7394210B2 (en) *	2004-09-29	2008-07-01	Tir Technology Lp	System and method for controlling luminaires
US10058621B2 (en)	2015-06-25	2018-08-28	Immunomedics, Inc.	Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en)	2013-07-23	2017-07-18	Immunomedics, Inc.	Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8349332B2 (en)	2005-04-06	2013-01-08	Ibc Pharmaceuticals, Inc.	Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en)	2005-04-06	2013-07-02	Ibc Pharmaceuticals, Inc.	Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US7452979B2 (en)	2005-08-02	2008-11-18	Arius Research, Inc.	Cancerous disease modifying antibodies
US7411046B2 (en)	2005-08-02	2008-08-12	Arius Research Inc	Cancerous disease modifying antibodies
US7456258B2 (en)	2005-08-02	2008-11-25	Arius Research, Inc.	Cancerous disease modifying antibodies
US7452978B2 (en) *	2005-08-02	2008-11-18	Arius Research, Inc.	Cancerous disease modifying antibodies
US7494648B2 (en) *	2005-08-02	2009-02-24	Hoffmann-La Roche Inc.	Cancerous disease modifying antibodies
US7456259B2 (en)	2005-08-02	2008-11-25	Arius Research, Inc.	Cancerous disease modifying antibodies
US20080305104A1 (en) *	2006-02-24	2008-12-11	Young David S F	Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US7420041B2 (en) *	2006-02-24	2008-09-02	Arius Research Inc.	Cytotoxicity mediation of cells evidencing surface expression of TROP-2
CA2643063A1 (en) *	2006-02-24	2007-08-30	Arius Research, Inc.	Cancerous disease modifying antibody 141205-02
WO2007095746A1 (en) *	2006-02-24	2007-08-30	Arius Research Inc.	Cancerous disease modifying antibodies
US20080089891A1 (en) *	2006-07-26	2008-04-17	Arius Research, Inc.	Cancerous disease modifying antibodies
BRPI0718609A8 (pt) *	2006-11-13	2015-09-29	Arius Res Inc	Anticorpos modificadores de doença cancerosa.
US8129502B2 (en) *	2006-11-13	2012-03-06	Hoffmann-La Roche Inc.	Cancerous disease modifying antibodies
AU2007321664A1 (en) *	2006-11-13	2008-05-22	F. Hoffmann-La Roche Ag	Cancerous disease modifying antibodies
US8003761B2 (en) *	2007-01-23	2011-08-23	Hoffmann-La Roche Inc.	Cancerous disease modifying antibodies
US20080206133A1 (en) *	2007-01-23	2008-08-28	Young David S F	Cancerous Disease Modifying Antibodies
KR20090114454A (ko) *	2007-03-26	2009-11-03	에프. 호프만-라 로슈 아게	하이브리도마 세포주 ａｒ５１ａ６３０.３ 에 의해 생성된 암 질환 조절 항체 ０１０２０７－０１.
WO2008134876A1 (en) *	2007-05-07	2008-11-13	F. Hoffmann-La Roche Ag	Cancerous disease modifying antibodies
US20090285751A1 (en) *	2008-04-10	2009-11-19	Young David S F	Cancerous disease modifying antibodies
US9650639B2 (en)	2008-05-19	2017-05-16	Advaxis, Inc.	Dual delivery system for heterologous antigens
EP2288379A4 (en)	2008-05-19	2012-08-08	Advaxis	DOUBLE RELEASE SYSTEM FOR HETEROLOGIST ANTIGENE
US9017660B2 (en)	2009-11-11	2015-04-28	Advaxis, Inc.	Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
WO2011004899A1 (en)	2009-07-06	2011-01-13	Takeda Pharmaceutical Company Limited	Cancerous disease modifying antibodies
US10016617B2 (en)	2009-11-11	2018-07-10	The Trustees Of The University Of Pennsylvania	Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2011085354A1 (en) *	2010-01-11	2011-07-14	Center For Molecular Medicine And Immunology	Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
JP5981436B2 (ja)	2010-10-01	2016-08-31	ザトラスティーズオブザユニバーシティオブペンシルバニア	寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
CA2829960A1 (en)	2011-03-11	2012-09-20	John Rothman	Listeria-based adjuvants
CA2853138A1 (en)	2011-12-05	2013-06-13	Immunomedics, Inc.	Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US9757458B2 (en)	2011-12-05	2017-09-12	Immunomedics, Inc.	Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
BR112014022662A2 (pt)	2012-03-12	2017-10-03	Advaxis Inc	Inibição da função de célula supressora seguindo tratamento de vacina de listeria
EP4035689A1 (en)	2012-12-13	2022-08-03	Immunomedics Inc.	Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US9107960B2 (en)	2012-12-13	2015-08-18	Immunimedics, Inc.	Antibody-SN-38 immunoconjugates with a CL2A linker
US10413539B2 (en)	2012-12-13	2019-09-17	Immunomedics, Inc.	Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10206918B2 (en)	2012-12-13	2019-02-19	Immunomedics, Inc.	Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10744129B2 (en)	2012-12-13	2020-08-18	Immunomedics, Inc.	Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9492566B2 (en)	2012-12-13	2016-11-15	Immunomedics, Inc.	Antibody-drug conjugates and uses thereof
US9931417B2 (en)	2012-12-13	2018-04-03	Immunomedics, Inc.	Antibody-SN-38 immunoconjugates with a CL2A linker
US10137196B2 (en)	2012-12-13	2018-11-27	Immunomedics, Inc.	Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US11253606B2 (en)	2013-07-23	2022-02-22	Immunomedics, Inc.	Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN107428837A (zh)	2015-04-22	2017-12-01	免疫医疗公司	循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
US10195175B2 (en)	2015-06-25	2019-02-05	Immunomedics, Inc.	Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US20170224837A1 (en)	2016-02-10	2017-08-10	Immunomedics, Inc.	Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
WO2017189279A1 (en)	2016-04-27	2017-11-02	Immunomedics, Inc.	Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
RU2758234C2 (ru)	2017-03-27	2021-10-26	Иммьюномедикс, Инк.	ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
EP3606964A4 (en)	2017-04-03	2020-12-09	Immunomedics, Inc.	SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4474893A (en) *	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4713352A (en) *	1981-08-31	1987-12-15	Sloan-Kettering Institute For Cancer Reseach	Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
US4612282A (en) *	1981-12-15	1986-09-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Monoclonal antibodies reactive with human breast cancer
US4507391A (en) *	1982-04-02	1985-03-26	Sloan-Kettering Institute For Cancer Research	Method for detecting the presence of GD3 ganglioside
US4713351A (en) *	1983-01-28	1987-12-15	The University Of Rochester	Monoclonal antibody directed to an antigen derived from human ovarian tumors and a radioimmunoassay using the antibody
US4579827A (en) *	1983-03-11	1986-04-01	Sloan-Kettering Institute For Cancer Research	Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4753894A (en) *	1984-02-08	1988-06-28	Cetus Corporation	Monoclonal anti-human breast cancer antibodies
ZA858371B (en) *	1984-11-02	1987-03-25	Oncogen	Monoclonal antibodies for human non-small cell lung carcinomas
IL76877A (en) *	1984-11-02	1991-11-21	Oncogen	Diagnostic method for the determination of human non-small cell lung carcinomas employing novel monoclonal antibodies and compositions containing said antibodies
US4708930A (en) *	1984-11-09	1987-11-24	Coulter Corporation	Monoclonal antibody to a human carcinoma tumor associated antigen
US4935495A (en) *	1984-12-21	1990-06-19	Oncogen	Monoclonal antibodies to the L6 glycolipid antigenic determinant found on human non-small cell lung carcinomas
US4906562A (en) *	1984-12-21	1990-03-06	Oncogen	Monocolonal antibodies and antigen for human non-small cell lung carcinomas
US4676980A (en) *	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5185432A (en) *	1986-02-26	1993-02-09	Oncogen	Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas
EP0323802A3 (en) *	1987-12-24	1989-07-26	Sandoz Ag	Monoclonal antibodies against, and cell surface antigen of, lung carcinoma
DE3809236A1 (de) *	1988-03-18	1989-09-28	Lohmann Therapie Syst Lts	Verwendung von ketogruppenhaltigen zyklischen verbindungen
US5171666A (en) *	1988-04-22	1992-12-15	Eli Lilly And Company	Monoclonal antibodies reactive with a cell-surface gylcoprotein expressed on human carcinomas
US5134075A (en) *	1989-02-17	1992-07-28	Oncogen Limited Partnership	Monoclonal antibody to novel antigen associated with human tumors
GB8925900D0 (en) *	1989-11-16	1990-01-04	Ici Plc	Reactive dyes

1989
- 1989-04-17 US US07/339,142 patent/US5171665A/en not_active Expired - Lifetime
1990
- 1990-03-22 IL IL9384090A patent/IL93840A/en not_active IP Right Cessation
- 1990-03-23 GR GR900100221A patent/GR1000477B/el unknown
- 1990-03-26 WO PCT/US1990/001621 patent/WO1990012594A1/en not_active Application Discontinuation
- 1990-03-26 KR KR1019910701368A patent/KR920700692A/ko not_active Application Discontinuation
- 1990-03-26 AU AU56714/90A patent/AU639458B2/en not_active Ceased
- 1990-03-26 JP JP2508122A patent/JPH04505102A/ja active Pending
- 1990-03-26 EP EP90908763A patent/EP0597829A1/en not_active Withdrawn
- 1990-04-10 CA CA002014304A patent/CA2014304A1/en not_active Abandoned
- 1990-04-12 NZ NZ233325A patent/NZ233325A/en unknown
- 1990-04-16 PT PT93776A patent/PT93776A/pt not_active Application Discontinuation
1991
- 1991-10-17 FI FI914908A patent/FI914908A0/fi not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU639458B2 (en)	1993-07-29
PT93776A (pt)	1991-02-08
JPH04505102A (ja)	1992-09-10
FI914908A0 (fi)	1991-10-17
US5171665A (en)	1992-12-15
GR900100221A (en)	1991-09-27
NZ233325A (en)	1992-04-28
GR1000477B (el)	1992-07-30
EP0597829A4 (en)	1992-02-27
IL93840A0 (en)	1990-12-23
KR920700692A (ko)	1992-08-10
AU5671490A (en)	1990-11-16
CA2014304A1 (en)	1990-10-17
WO1990012594A1 (en)	1990-11-01
EP0597829A1 (en)	1994-05-25

Legal Events

Date	Code	Title	Description
1996-06-18	KB	Patent renewed
2001-06-14	RH	Patent void

Publication	Publication Date	Title
AU639458B2 (en)	1993-07-29	Novel monoclonal antibody to novel antigen associated with human tumors
US5134075A (en)	1992-07-28	Monoclonal antibody to novel antigen associated with human tumors
EP0375562B1 (en)	1995-04-26	Novel monoclonal antibody to human carcinomas
US5491088A (en)	1996-02-13	Monoclonal antibody BR 96 and chimeric monoclonal antibodies having the variable region of MAB BR96, which bind to a variant of ley antigen on human carcimona cells
CA1215331A (en)	1986-12-16	Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US5185432A (en)	1993-02-09	Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas
US5411884A (en)	1995-05-02	Monoclonal antibody L53 which recognizes a human tumor-associated antigen
US20110097747A1 (en)	2011-04-28	Monoclonal antibody binds antigen associated with human tumors
US20130330742A1 (en)	2013-12-12	Assay for colon and other cancers in humans
WO1990006772A1 (en)	1990-06-28	Novel monoclonal antibody to human carcinomas